160 related articles for article (PubMed ID: 25809558)
1. Benzo[b]tryptanthrin inhibits MDR1, topoisomerase activity, and reverses adriamycin resistance in breast cancer cells.
Jun KY; Park SE; Liang JL; Jahng Y; Kwon Y
ChemMedChem; 2015 May; 10(5):827-35. PubMed ID: 25809558
[TBL] [Abstract][Full Text] [Related]
2. Design, synthesis, topoisomerase I & II inhibitory activity, antiproliferative activity, and structure-activity relationship study of pyrazoline derivatives: An ATP-competitive human topoisomerase IIα catalytic inhibitor.
Ahmad P; Woo H; Jun KY; Kadi AA; Abdel-Aziz HA; Kwon Y; Rahman AF
Bioorg Med Chem; 2016 Apr; 24(8):1898-908. PubMed ID: 26988802
[TBL] [Abstract][Full Text] [Related]
3. Synthesis of benzo-annulated tryptanthrins and their biological properties.
Liang JL; Park SE; Kwon Y; Jahng Y
Bioorg Med Chem; 2012 Aug; 20(16):4962-7. PubMed ID: 22819942
[TBL] [Abstract][Full Text] [Related]
4. Tryptanthrin inhibits MDR1 and reverses doxorubicin resistance in breast cancer cells.
Yu ST; Chen TM; Tseng SY; Chen YH
Biochem Biophys Res Commun; 2007 Jun; 358(1):79-84. PubMed ID: 17482571
[TBL] [Abstract][Full Text] [Related]
5. Development of 13H-benzo[f]chromeno[4,3-b][1,7]naphthyridines and their salts as potent cytotoxic agents and topoisomerase I/IIα inhibitors.
Arepalli SK; Lee C; Sim S; Lee K; Jo H; Jun KY; Kwon Y; Kang JS; Jung JK; Lee H
Bioorg Med Chem; 2018 Oct; 26(18):5181-5193. PubMed ID: 30253887
[TBL] [Abstract][Full Text] [Related]
6. A series of novel terpyridine-skeleton molecule derivants inhibit tumor growth and metastasis by targeting topoisomerases.
Kwon HB; Park C; Jeon KH; Lee E; Park SE; Jun KY; Kadayat TM; Thapa P; Karki R; Na Y; Park MS; Rho SB; Lee ES; Kwon Y
J Med Chem; 2015 Feb; 58(3):1100-22. PubMed ID: 25603122
[TBL] [Abstract][Full Text] [Related]
7. Downregulation of GSTpi expression by tryptanthrin contributing to sensitization of doxorubicin-resistant MCF-7 cells through c-jun NH2-terminal kinase-mediated apoptosis.
Yu ST; Chen TM; Chern JW; Tseng SY; Chen YH
Anticancer Drugs; 2009 Jun; 20(5):382-8. PubMed ID: 19318911
[TBL] [Abstract][Full Text] [Related]
8. Oxocrebanine: A Novel Dual Topoisomerase inhibitor, Suppressed the Proliferation of Breast Cancer Cells MCF-7 by Inducing DNA Damage and Mitotic Arrest.
Yu L; Han S; Lang L; Song H; Zhang C; Dong L; Jia S; Zhang Y; Xiao D; Liu J; Xu Y; Zhang X
Phytomedicine; 2021 Apr; 84():153504. PubMed ID: 33611211
[TBL] [Abstract][Full Text] [Related]
9. Reduced activity of topoisomerase II in an Adriamycin-resistant human stomach-adenocarcinoma cell line.
Son YS; Suh JM; Ahn SH; Kim JC; Yi JY; Hur KC; Hong WS; Muller MT; Chung IK
Cancer Chemother Pharmacol; 1998; 41(5):353-60. PubMed ID: 9523730
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and biological evaluation of benzo[a]phenazine derivatives as a dual inhibitor of topoisomerase I and II.
Zhuo ST; Li CY; Hu MH; Chen SB; Yao PF; Huang SL; Ou TM; Tan JH; An LK; Li D; Gu LQ; Huang ZS
Org Biomol Chem; 2013 Jun; 11(24):3989-4005. PubMed ID: 23657605
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis and systematic evaluation of cytotoxic 3-heteroarylisoquinolinamines as topoisomerases inhibitors.
My Van HT; Woo H; Jeong HM; Khadka DB; Yang SH; Zhao C; Jin Y; Lee ES; Youl Lee K; Kwon Y; Cho WJ
Eur J Med Chem; 2014 Jul; 82():181-94. PubMed ID: 24904965
[TBL] [Abstract][Full Text] [Related]
12. Synthesis, Biological Evaluation and Molecular Docking Study of Cyclic Diarylheptanoids as Potential Anticancer Therapeutics.
Lu Y; Yin W; Alam MS; Kadi AA; Jahng Y; Kwon Y; Rahman AFMM
Anticancer Agents Med Chem; 2020; 20(4):464-475. PubMed ID: 31763968
[TBL] [Abstract][Full Text] [Related]
13. Induction of sensitivity to doxorubicin and etoposide by transfection of MCF-7 breast cancer cells with heregulin beta-2.
Harris LN; Yang L; Tang C; Yang D; Lupu R
Clin Cancer Res; 1998 Apr; 4(4):1005-12. PubMed ID: 9563896
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis and biological evaluation of novel 7-alkylamino substituted benzo[a]phenazin derivatives as dual topoisomerase I/II inhibitors.
Yao BL; Mai YW; Chen SB; Xie HT; Yao PF; Ou TM; Tan JH; Wang HG; Li D; Huang SL; Gu LQ; Huang ZS
Eur J Med Chem; 2015 Mar; 92():540-53. PubMed ID: 25599951
[TBL] [Abstract][Full Text] [Related]
15. Evodiamine, a dual catalytic inhibitor of type I and II topoisomerases, exhibits enhanced inhibition against camptothecin resistant cells.
Pan X; Hartley JM; Hartley JA; White KN; Wang Z; Bligh SW
Phytomedicine; 2012 May; 19(7):618-24. PubMed ID: 22402246
[TBL] [Abstract][Full Text] [Related]
16. Nitric oxide inhibits topoisomerase II activity and induces resistance to topoisomerase II-poisons in human tumor cells.
Kumar A; Ehrenshaft M; Tokar EJ; Mason RP; Sinha BK
Biochim Biophys Acta; 2016 Jul; 1860(7):1519-27. PubMed ID: 27095671
[TBL] [Abstract][Full Text] [Related]
17. Aconitine linoleate, a natural lipo-diterpenoid alkaloid, stimulates anti-proliferative activity reversing doxorubicin resistance in MCF-7/ADR breast cancer cells as a selective topoisomerase IIα inhibitor.
Luan S; Gao Y; Liang X; Zhang L; Wu Q; Hu Y; Yin L; He C; Liu S
Naunyn Schmiedebergs Arch Pharmacol; 2022 Jan; 395(1):65-76. PubMed ID: 34727218
[TBL] [Abstract][Full Text] [Related]
18. Characterization of novel human leukemic cell lines selected for resistance to merbarone, a catalytic inhibitor of DNA topoisomerase II.
Kusumoto H; Rodgers QE; Boege F; Raimondi SC; Beck WT
Cancer Res; 1996 Jun; 56(11):2573-83. PubMed ID: 8653700
[TBL] [Abstract][Full Text] [Related]
19. Modification of topoisomerases in mammospheres derived from breast cancer cell line: clinical implications for combined treatments with tyrosine kinase inhibitors.
Peleg R; Romzova M; Kogan-Zviagin I; Apte RN; Priel E
BMC Cancer; 2014 Dec; 14():910. PubMed ID: 25472619
[TBL] [Abstract][Full Text] [Related]
20. Decreased DNA topoisomerase II alpha expression and cold-sensitive growth in a mouse mammary cancer cell line resistant to etoposide and doxorubicin.
Kawanami K; Nakamura T; Ono M; Kusano T; Okada K; Kikuchi A; Adachi N; Kohno K; Higashi K; Kuwano M
Oncol Res; 1996; 8(5):197-206. PubMed ID: 8884812
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]